Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and decided to rebuild anew. Now, watching the pipeline he helped remold finally bear fruit, Hoos is ready for a new challenge — and it will come at a tiny biotech at the frontier of “precision medicine 2.0.”
